Tenet Healthcare (THC) Projected to Announce Quarterly Earnings on Friday

Tenet Healthcare (NYSE:THC) is projected to issue its Q2 2026 results before the market opens on Friday, July 24th. Analysts expect Tenet Healthcare to post earnings of $4.26 per share and revenue of $5.4316 billion for the quarter. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, July 24, 2026 at 11:30 AM ET.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings data on Thursday, April 30th. The company reported $4.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.21 by $0.61. The firm had revenue of $5.37 billion for the quarter, compared to analysts’ expectations of $5.39 billion. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $4.36 earnings per share. On average, analysts expect Tenet Healthcare to post $18 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Tenet Healthcare Stock Up 0.9%

Shares of NYSE THC opened at $196.19 on Wednesday. The stock has a market cap of $16.90 billion, a P/E ratio of 10.20, a P/E/G ratio of 1.61 and a beta of 1.27. Tenet Healthcare has a 52-week low of $146.60 and a 52-week high of $247.21. The company has a debt-to-equity ratio of 1.96, a quick ratio of 1.30 and a current ratio of 1.36. The firm has a 50 day moving average price of $184.41 and a 200 day moving average price of $197.39.

Analyst Ratings Changes

A number of equities research analysts recently commented on THC shares. Morgan Stanley set a $254.00 price objective on shares of Tenet Healthcare in a report on Friday, May 1st. KeyCorp decreased their price objective on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Robert W. Baird decreased their price objective on shares of Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, May 5th. Barclays upped their price objective on Tenet Healthcare from $238.00 to $240.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Finally, Guggenheim lowered their price objective on Tenet Healthcare from $252.00 to $242.00 and set a “buy” rating on the stock in a research note on Monday. Eighteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Tenet Healthcare has an average rating of “Moderate Buy” and a consensus target price of $244.84.

Insiders Place Their Bets

In related news, Director J Robert Kerrey sold 5,638 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $174.52, for a total transaction of $983,943.76. Following the sale, the director owned 16,804 shares in the company, valued at $2,932,634.08. This represents a 25.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total value of $532,050.00. Following the completion of the sale, the director owned 24,805 shares of the company’s stock, valued at approximately $4,399,166.75. This represents a 10.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.97% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tenet Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP grew its position in shares of Tenet Healthcare by 1,114.2% during the 4th quarter. Wellington Management Group LLP now owns 1,135,801 shares of the company’s stock valued at $225,706,000 after acquiring an additional 1,042,260 shares during the period. Boston Partners grew its holdings in Tenet Healthcare by 38.8% during the 3rd quarter. Boston Partners now owns 3,147,555 shares of the company’s stock valued at $638,958,000 after buying an additional 880,413 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Tenet Healthcare by 62.3% in the third quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock worth $380,989,000 after purchasing an additional 720,160 shares during the period. Alliancebernstein L.P. grew its holdings in shares of Tenet Healthcare by 375.7% during the second quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock worth $139,085,000 after purchasing an additional 624,125 shares in the last quarter. Finally, 8 Knots Management LLC bought a new position in Tenet Healthcare in the second quarter valued at $48,498,000. 95.44% of the stock is owned by hedge funds and other institutional investors.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.